What are the major opportunities in the Acute Intermittent Porphyria market? What are the strategies for the Acute Intermittent Porphyria market?

For detailed insights on the major opportunities and strategies in the Acute Intermittent Porphyria market, Read More

How does the Acute Intermittent Porphyria market relate to the overall economy and other similar markets?

For detailed insights on Acute Intermittent Porphyria's relation to the overall economy and other similar markets, Read More

What are the key dynamics influencing the Acute Intermittent Porphyria market growth? SWOT analysis of the Acute Intermittent Porphyria market.

For detailed insights on the key dynamics influencing the Acute Intermittent Porphyria market growth and SWOT analysis of the Acute Intermittent Porphyria industry, Read More

Global Acute Intermittent Porphyria Market Report 2025

Item added to cart!

Report Price : $4490.00

Pages : 175

Format : PDF

Published : December 2025

Delivery Time : 2-3 Business Days

Purchase This Report Download Sample PDF

Purchase This Report

Acute Intermittent Porphyria Global Market Report 2025

Name: Acute Intermittent Porphyria Global Market Report 2025
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

By Diagnosis (Urine Test, Blood Test, Serum Test, DNA Test, Other Diagnosis), By Treatment (Prophylactic Hematin Infusions, Gonadotropin-Releasing Hormone Analogues, Other Treatments), By End-Users (Hospitals And Clinics, Ambulatory Surgical Centers, Research Centers) – Market Size, Trends, And Global Forecast 2025-2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

What Is Covered Under Acute Intermittent Porphyria Market?

Acute intermittent porphyria (AIP) is a rare genetic disorder that affects the production of heme, a vital component of hemoglobin in the blood. AIP is characterized by intermittent attacks of severe abdominal pain, gastrointestinal disturbances, and neurological symptoms, including muscle weakness, seizures, and mental changes such as anxiety, confusion, or hallucinations.

The main acute intermittent porphyria diagnoses include urine tests, blood tests, serum tests, DNA tests, and others. The urine test method involves analyzing a sample of urine to detect elevated levels of porphyrins or their precursors, which are indicators of acute intermittent porphyria (AIP). It offers various types of treatments, such as prophylactic hematin infusions, gonadotropin-releasing hormone analogues, and others, and it is used by hospitals and clinics, ambulatory surgical centers, and research centers.

Acute Intermittent Porphyria Market Size and growth rate 2025 to 2029: Graph

What Is The Acute Intermittent Porphyria Market Size 2025 And Growth Rate?

The acute intermittent porphyria market size has grown strongly in recent years. It will grow from $4.37 billion in 2024 to $4.66 billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to rising healthcare expenditure, growth in biopharmaceuticals market, rising prevalence of genetic disorders, expansion of telemedicine services, and growing focus on early detection.

What Is The Acute Intermittent Porphyria Market Growth Forecast?

The acute intermittent porphyria market size is expected to see strong growth in the next few years. It will grow to $5.96 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to increasing incidence of acute intermittent porphyria, growing awareness of rare diseases, supportive government policies, growing patient advocacy, and expansion of genetic testing services. Major trends in the forecast period include advancements in diagnostic techniques, development of novel therapeutic options, investment in research and development, collaborations between pharma companies, and technological innovations in treatment.

Book your 30 minutes free consultation with our research experts

How Is The Acute Intermittent Porphyria Market Segmented?

The acute intermittent porphyriamarket covered in this report is segmented –

1) By Diagnosis: Urine Test, Blood Test, Serum Test, DNA Test, Other Diagnosis

2) By Treatment: Prophylactic Hematin Infusions, Gonadotropin-Releasing Hormone Analogues, Other Treatments

3) By End-Users: Hospitals And Clinics, Ambulatory Surgical Centers, Research Centers

Subsegments:

1) By Urine Test: Urine Porphobilinogen (PBG) Test, Urine Aminolevulinic Acid (ALA) Test, Urine Color Change Test

2) By Blood Test: Plasma Porphyrin Levels Test, Blood Aminolevulinic Acid (ALA) Test, Complete Blood Count (CBC) Test

3) By Serum Test: Serum Porphyrin Levels Test, Liver Function Test (LFT), Serum ALA and PBG Enzyme Test

4) By DNA Test: Genetic Mutation Testing, Gene Sequencing Test

5) By Other Diagnosis: Stool Test for Porphyrins, Imaging Tests (CT/MRI Scans for Complications), Enzyme Activity Assays.

What Is Driving The Acute Intermittent Porphyria Market? Impact Of Rising Metabolic Disorders On The Growth Of The Acute Intermittent Porphyria Market

The prevalence of metabolic disorders is expected to propel the growth of the acute intermittent porphyria market going forward. Metabolic disorders are a group of conditions that occur due to abnormal chemical reactions in the body that disrupt the normal process of metabolism. The prevalence of metabolic disorders is due to genetic factors, lifestyle factors, environmental influences, and increased awareness and diagnosis. The rise in metabolic disorders is encouraging the pharmaceutical industry to invest in treatments for rare and genetic conditions such as acute intermittent porphyria. For instance, in December 2023, according to Cleveland Clinic, a US-based nonprofit academic medical center, inherited metabolic disorders collectively impact approximately 1 in 1,000 to 2,500 births worldwide. Therefore, the prevalence of metabolic disorders is driving the growth of the acute intermittent porphyria market.

Who Are The Major Players In The Global Acute Intermittent Porphyria Market?

Major companies operating in the acute intermittent porphyria market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi SA, AstraZeneca Plc, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited, Vertex Pharmaceuticals Inc., Eisai Co. Ltd., Octapharma AG, BioMarin Pharmaceutical Inc., Swedish Orphan Biovitrum AB, Alnylam Pharmaceuticals Inc., Mylan N.V., Clinuvel Pharmaceuticals Ltd., Recordati Rare Diseases Inc.

What Are The Key Trends Of The Global Acute Intermittent Porphyria Market? Innovations In Acute Intermittent Porphyria Management

Major companies operating in the acute intermittent porphyria market are focused on developing innovative products, such as acute intermittent porphyria management tablets, to serve customers with advanced features better. Acute intermittent porphyria management tablets refer to oral medications used to manage or prevent the symptoms and acute attacks associated with AIP. For instance, in October 2023, Alembic Pharmaceuticals Ltd., an India-based pharmaceutical company, announced the US Food & Drug Administration (USFDA) approval for its Chlorpromazine Hydrochloride Tablets USP, 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg. Chlorpromazine hydrochloride tablets USP, available in doses of 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg, are used to manage the symptoms of psychotic disorders and treat schizophrenia. They also help control nausea and vomiting, alleviate restlessness and apprehension before surgery, and serve as an adjunct in treating tetanus. Additionally, these tablets are utilized in the management of acute intermittent porphyria, control manic symptoms of manic-depressive illness, and provide relief from intractable hiccups.

Need data on a specific region in this market?

Request Regional Data

What Are Latest Mergers And Acquisitions In The Acute Intermittent Porphyria Market? American Porphyria Foundation Partners With Recordati Rare Diseases To Advance AIP Awareness And Support

In April 2024, the American Porphyria Foundation (APF), a US-based non-profit organization, partnered with Recordati Rare Diseases. Through this partnership, the American Porphyria Foundation (APF) aims to raise awareness of porphyria and enhance public understanding and support for AIP. Recordati Rare Diseases is an Italy-based pharmaceutical company treating acute intermittent porphyria (AIP).

What Is The Regional Outlook For The Global Acute Intermittent Porphyria Market?

North America was the largest region in the acute intermittent porphyria market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute intermittent porphyria market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the acute intermittent porphyria market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Acute Intermittent Porphyria Market?

The acute intermittent porphyria market consists of revenues earned by entities by providing services such as genetic testing, clinical consultation, treatment planning and medication management. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute intermittent porphyria market also includes sales of symptom management products, medical devices, nutritional supplements and emergency kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Acute Intermittent Porphyria Industry?

The acute intermittent porphyria market research report is one of a series of new reports from The Business Research Company that provides acute intermittent porphyria market statistics, including acute intermittent porphyria industry global market size, regional shares, competitors with a acute intermittent porphyria market share, detailed acute intermittent porphyria market segments, market trends and opportunities, and any further data you may need to thrive in the acute intermittent porphyria industry. This acute intermittent porphyria market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Acute Intermittent Porphyria Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	$4.66 billion
Revenue Forecast In 2034	$5.96 billion
Growth Rate	CAGR of 6.3% from 2025 to 2034
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	1) By Diagnosis: Urine Test, Blood Test, Serum Test, DNA Test, Other Diagnosis 2) By Treatment: Prophylactic Hematin Infusions, Gonadotropin-Releasing Hormone Analogues, Other Treatments 3) By End-Users: Hospitals And Clinics, Ambulatory Surgical Centers, Research Centers Subsegments: 1) By Urine Test: Urine Porphobilinogen (PBG) Test, Urine Aminolevulinic Acid (ALA) Test, Urine Color Change Test 2) By Blood Test: Plasma Porphyrin Levels Test, Blood Aminolevulinic Acid (ALA) Test, Complete Blood Count (CBC) Test 3) By Serum Test: Serum Porphyrin Levels Test, Liver Function Test (LFT), Serum ALA and PBG Enzyme Test 4) By DNA Test: Genetic Mutation Testing, Gene Sequencing Test 5) By Other Diagnosis: Stool Test for Porphyrins, Imaging Tests (CT/MRI Scans for Complications), Enzyme Activity Assays.
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi SA, AstraZeneca Plc, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited, Vertex Pharmaceuticals Inc., Eisai Co. Ltd., Octapharma AG, BioMarin Pharmaceutical Inc., Swedish Orphan Biovitrum AB, Alnylam Pharmaceuticals Inc., Mylan N.V., Clinuvel Pharmaceuticals Ltd., Recordati Rare Diseases Inc.
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

2. Acute Intermittent Porphyria Market Characteristics

3. Acute Intermittent Porphyria Market Trends And Strategies

4. Acute Intermittent Porphyria Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Acute Intermittent Porphyria Growth Analysis And Strategic Analysis Framework

5.1. Global Acute Intermittent Porphyria PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Acute Intermittent Porphyria Market Growth Rate Analysis

5.4. Global Acute Intermittent Porphyria Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Acute Intermittent Porphyria Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Acute Intermittent Porphyria Total Addressable Market (TAM)

6. Acute Intermittent Porphyria Market Segmentation

6.1. Global Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Urine Test

Blood Test

Serum Test

DNA Test

Other Diagnosis

6.2. Global Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Prophylactic Hematin Infusions

Gonadotropin-Releasing Hormone Analogues

Other Treatments

6.3. Global Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals and Clinics

Ambulatory Surgical Centers

Research Centers

6.4. Global Acute Intermittent Porphyria Market, Sub-Segmentation Of Urine Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Urine Porphobilinogen (PBG) Test

Urine Aminolevulinic Acid (ALA) Test

Urine Color Change Test

6.5. Global Acute Intermittent Porphyria Market, Sub-Segmentation Of Blood Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Plasma Porphyrin Levels Test

Blood Aminolevulinic Acid (ALA) Test

Complete Blood Count (CBC) Test

6.6. Global Acute Intermittent Porphyria Market, Sub-Segmentation Of Serum Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Serum Porphyrin Levels Test

Liver Function Test (LFT)

Serum ALA and PBG Enzyme Test

6.7. Global Acute Intermittent Porphyria Market, Sub-Segmentation Of DNA Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Genetic Mutation Testing

Gene Sequencing Test

6.8. Global Acute Intermittent Porphyria Market, Sub-Segmentation Of Other Diagnosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Stool Test for Porphyrins

Imaging Tests (CT/MRI Scans for Complications)

Enzyme Activity Assays

7. Acute Intermittent Porphyria Market Regional And Country Analysis

7.1. Global Acute Intermittent Porphyria Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Acute Intermittent Porphyria Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Acute Intermittent Porphyria Market

8.1. Asia-Pacific Acute Intermittent Porphyria Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Acute Intermittent Porphyria Market

9.1. China Acute Intermittent Porphyria Market Overview

9.2. China Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Acute Intermittent Porphyria Market

10.1. India Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Acute Intermittent Porphyria Market

11.1. Japan Acute Intermittent Porphyria Market Overview

11.2. Japan Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Acute Intermittent Porphyria Market

12.1. Australia Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Acute Intermittent Porphyria Market

13.1. Indonesia Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Acute Intermittent Porphyria Market

14.1. South Korea Acute Intermittent Porphyria Market Overview

14.2. South Korea Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Acute Intermittent Porphyria Market

15.1. Western Europe Acute Intermittent Porphyria Market Overview

15.2. Western Europe Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Acute Intermittent Porphyria Market

16.1. UK Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Acute Intermittent Porphyria Market

17.1. Germany Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Acute Intermittent Porphyria Market

18.1. France Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Acute Intermittent Porphyria Market

19.1. Italy Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Acute Intermittent Porphyria Market

20.1. Spain Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Acute Intermittent Porphyria Market

21.1. Eastern Europe Acute Intermittent Porphyria Market Overview

21.2. Eastern Europe Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Acute Intermittent Porphyria Market

22.1. Russia Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Acute Intermittent Porphyria Market

23.1. North America Acute Intermittent Porphyria Market Overview

23.2. North America Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Acute Intermittent Porphyria Market

24.1. USA Acute Intermittent Porphyria Market Overview

24.2. USA Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Acute Intermittent Porphyria Market

25.1. Canada Acute Intermittent Porphyria Market Overview

25.2. Canada Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Acute Intermittent Porphyria Market

26.1. South America Acute Intermittent Porphyria Market Overview

26.2. South America Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Acute Intermittent Porphyria Market

27.1. Brazil Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Acute Intermittent Porphyria Market

28.1. Middle East Acute Intermittent Porphyria Market Overview

28.2. Middle East Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Acute Intermittent Porphyria Market

29.1. Africa Acute Intermittent Porphyria Market Overview

29.2. Africa Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Acute Intermittent Porphyria Market Competitive Landscape And Company Profiles

30.1. Acute Intermittent Porphyria Market Competitive Landscape

30.2. Acute Intermittent Porphyria Market Company Profiles

30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Acute Intermittent Porphyria Market Other Major And Innovative Companies

31.1. Sanofi SA

31.2. AstraZeneca Plc

31.3. Novartis AG

31.4. GlaxoSmithKline Plc

31.5. Takeda Pharmaceutical Company Limited

31.6. Eli Lilly and Company

31.7. Gilead Sciences Inc.

31.8. Amgen Inc.

31.9. Novo Nordisk A/S

31.10. Regeneron Pharmaceuticals Inc.

31.11. Daiichi Sankyo Company Limited

31.12. Vertex Pharmaceuticals Inc.

31.13. Eisai Co. Ltd.

31.14. Octapharma AG

31.15. BioMarin Pharmaceutical Inc.

32. Global Acute Intermittent Porphyria Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Acute Intermittent Porphyria Market

34. Recent Developments In The Acute Intermittent Porphyria Market

35. Acute Intermittent Porphyria Market High Potential Countries, Segments and Strategies

35.1 Acute Intermittent Porphyria Market In 2029 - Countries Offering Most New Opportunities

35.2 Acute Intermittent Porphyria Market In 2029 - Segments Offering Most New Opportunities

35.3 Acute Intermittent Porphyria Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Billion

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Table 3: Global Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 4: Global Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 5: Global Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 6: Global Acute Intermittent Porphyria Market, Sub-Segmentation Of Urine Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 7: Global Acute Intermittent Porphyria Market, Sub-Segmentation Of Blood Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 8: Global Acute Intermittent Porphyria Market, Sub-Segmentation Of Serum Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 9: Global Acute Intermittent Porphyria Market, Sub-Segmentation Of DNA Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 10: Global Acute Intermittent Porphyria Market, Sub-Segmentation Of Other Diagnosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 11: Global Acute Intermittent Porphyria Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 12: Global Acute Intermittent Porphyria Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 13: Asia-Pacific, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 14: Asia-Pacific, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 15: Asia-Pacific, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 16: China, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 17: China, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 18: China, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 19: India, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 20: India, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 21: India, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 22: Japan, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 23: Japan, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 24: Japan, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 25: Australia, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 26: Australia, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 27: Australia, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 28: Indonesia, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 29: Indonesia, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 30: Indonesia, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 31: South Korea, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 32: South Korea, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 33: South Korea, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 34: Western Europe, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 35: Western Europe, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 36: Western Europe, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 37: UK, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 38: UK, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 39: UK, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 40: Germany, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 41: Germany, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 42: Germany, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 43: France, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 44: France, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 45: France, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 46: Italy, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 47: Italy, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 48: Italy, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 49: Spain, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 50: Spain, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 51: Spain, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 52: Eastern Europe, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 53: Eastern Europe, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 54: Eastern Europe, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 55: Russia, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 56: Russia, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 57: Russia, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 58: North America, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 59: North America, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 60: North America, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 61: USA, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 62: USA, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 63: USA, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 64: Canada, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 65: Canada, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 66: Canada, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 67: South America, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 68: South America, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 69: South America, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 70: Brazil, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 71: Brazil, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 72: Brazil, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 73: Middle East, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 74: Middle East, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 75: Middle East, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 76: Africa, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 77: Africa, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 78: Africa, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 79: Pfizer Inc. Financial Performance

Table 80: Johnson & Johnson Financial Performance

Table 81: Roche Holding AG Financial Performance

Table 82: Merck & Co. Inc. Financial Performance

Table 83: AbbVie Inc. Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Billion

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Figure 3: Global Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 4: Global Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 5: Global Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 6: Global Acute Intermittent Porphyria Market, Sub-Segmentation Of Urine Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 7: Global Acute Intermittent Porphyria Market, Sub-Segmentation Of Blood Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 8: Global Acute Intermittent Porphyria Market, Sub-Segmentation Of Serum Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 9: Global Acute Intermittent Porphyria Market, Sub-Segmentation Of DNA Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 10: Global Acute Intermittent Porphyria Market, Sub-Segmentation Of Other Diagnosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 11: Global Acute Intermittent Porphyria Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 12: Global Acute Intermittent Porphyria Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 13: Asia-Pacific, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 14: Asia-Pacific, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 15: Asia-Pacific, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 16: China, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 17: China, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 18: China, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 19: India, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 20: India, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 21: India, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 22: Japan, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 23: Japan, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 24: Japan, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 25: Australia, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 26: Australia, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 27: Australia, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 28: Indonesia, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 29: Indonesia, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 30: Indonesia, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 31: South Korea, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 32: South Korea, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 33: South Korea, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 34: Western Europe, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 35: Western Europe, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 36: Western Europe, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 37: UK, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 38: UK, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 39: UK, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 40: Germany, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 41: Germany, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 42: Germany, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 43: France, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 44: France, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 45: France, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 46: Italy, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 47: Italy, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 48: Italy, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 49: Spain, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 50: Spain, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 51: Spain, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 52: Eastern Europe, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 53: Eastern Europe, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 54: Eastern Europe, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 55: Russia, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 56: Russia, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 57: Russia, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 58: North America, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 59: North America, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 60: North America, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 61: USA, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 62: USA, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 63: USA, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 64: Canada, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 65: Canada, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 66: Canada, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 67: South America, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 68: South America, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 69: South America, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 70: Brazil, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 71: Brazil, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 72: Brazil, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 73: Middle East, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 74: Middle East, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 75: Middle East, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 76: Africa, Acute Intermittent Porphyria Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 77: Africa, Acute Intermittent Porphyria Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 78: Africa, Acute Intermittent Porphyria Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 79: Pfizer Inc. Financial Performance

Figure 80: Johnson & Johnson Financial Performance

Figure 81: Roche Holding AG Financial Performance

Figure 82: Merck & Co. Inc. Financial Performance

Figure 83: AbbVie Inc. Financial Performance

Global Complete Nutrition Products Market Landscape: Trends and Market Share to 2029

Competitive and Market Trend Analysis of Conjugate Vaccine Industry Through 2029

Industry Trends Show Cosmeceuticals Market Set to Expand at 8.8% CAGR Until 2029

Strategic Report on Cosmetic Ingredients Market: Growth Opportunities and Emerging Challenges

A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

A 2025 analysis tracking API pricing, competitive landscape, and growth strategies in the losartan potassium active pharmaceutical ingredient market.

Acute Ischemic Stroke Drugs Global Market Report 2025 – By Type (Tablet, Capsule, Other Types), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Application (Hospitals, Diagnostic C...

Post-Acute Care Global Market Report 2025 – By Service (Skilled Nursing Facilities, Inpatient Rehabilitation Facilities, Long Term Care Hospitals, Hospice Care, Home Healthcare Agencies, Other Services), By Conditions (A...

Acute Pancreatitis Global Market Report 2025 – By Cause (Gallstones, Alcohol, Other Causes), By Treatment (Intravenous Fluid, Nutritional Support, Analgesics, Endoscopic Retrograde Cholangiopancreatography (ERCP), Other ...

Acute Ischemic Stroke Diagnosis Global Market Report 2025 – By Diagnostic Type (Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Carotid Ultrasound, Cerebral Angiography, Electrocardiography (ECG), Echocardiog...

Acute Spinal Cord Injury Global Market Report 2025 – By Type (Complete Spinal Cord Injury, Incomplete Spinal Cord Injury), By Diagnosis Type (Laboratory Tests, Imaging Tests), By Application (Hospitals, Clinics) – Impact...

Acute Coronary Syndrome Global Market Report 2025 – By Type (Non-St-Elevation Myocardial Infarction, St-Elevation Myocardial Infarction, Unstable Angina), By Treatment (Medications, Statins, Beta blockers, ACE inhibitors...

Acute Respiratory Distress Syndrome (ARDS) Global Market Report 2025 – By Type (Diagnosis, Treatment), By Cause (COVID-19 Disease 2019 (COVID-19), Sepsis, Inhalation Of Harmful Substances, Severe Pneumonia, Other Causes)...

Frequently Asked Questions

What is the definition of the Acute Intermittent Porphyria market?

How will the Acute Intermittent Porphyria market drivers and restraints affect the market dynamics? What forces will shape the Acute Intermittent Porphyria industry going forward?

The Acute Intermittent Porphyria market major growth driver - Impact Of Rising Metabolic Disorders On The Growth Of The Acute Intermittent Porphyria Market. For further insights on the Acute Intermittent Porphyria market, request a sample here

What is the forecast market size or the forecast market value of the Acute Intermittent Porphyria market?

The Acute Intermittent Porphyria market size has grown strongly in recent years. The acute intermittent porphyria market size has grown strongly in recent years. It will grow from $4.37 $ billion in 2024 to $4.66 $ billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to rising healthcare expenditure, growth in biopharmaceuticals market, rising prevalence of genetic disorders, expansion of telemedicine services, and growing focus on early detection. The acute intermittent porphyria market size is expected to see strong growth in the next few years. It will grow to $5.96 $ billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to increasing incidence of acute intermittent porphyria, growing awareness of rare diseases, supportive government policies, growing patient advocacy, and expansion of genetic testing services. Major trends in the forecast period include advancements in diagnostic techniques, development of novel therapeutic options, investment in research and development, collaborations between pharma companies, and technological innovations in treatment. For further insights on the Acute Intermittent Porphyria market, request a sample here

How is the Acute Intermittent Porphyria market segmented?

The acute intermittent porphyriamarket covered in this report is segmented –
1) By Diagnosis: Urine Test, Blood Test, Serum Test, DNA Test, Other Diagnosis
2) By Treatment: Prophylactic Hematin Infusions, Gonadotropin-Releasing Hormone Analogues, Other Treatments
3) By End-Users: Hospitals And Clinics, Ambulatory Surgical Centers, Research Centers
Subsegments:
1) By Urine Test: Urine Porphobilinogen (PBG) Test, Urine Aminolevulinic Acid (ALA) Test, Urine Color Change Test
2) By Blood Test: Plasma Porphyrin Levels Test, Blood Aminolevulinic Acid (ALA) Test, Complete Blood Count (CBC) Test
3) By Serum Test: Serum Porphyrin Levels Test, Liver Function Test (LFT), Serum ALA and PBG Enzyme Test
4) By DNA Test: Genetic Mutation Testing, Gene Sequencing Test
5) By Other Diagnosis: Stool Test for Porphyrins, Imaging Tests (CT/MRI Scans for Complications), Enzyme Activity Assays. For further insights on the Acute Intermittent Porphyria market, request a sample here

Which region has the largest share of the Acute Intermittent Porphyria market? What are the other regions covered in the report?

North America was the largest region in the acute intermittent porphyria market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute intermittent porphyria market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on the Acute Intermittent Porphyria market, request a sample here.

Who are the major players in the Acute Intermittent Porphyria market?

What are the key trends in the Acute Intermittent Porphyria market?

Major trends in the Acute Intermittent Porphyria market include Innovations In Acute Intermittent Porphyria Management. For further insights on the Acute Intermittent Porphyria market, request a sample here.